Clinical Trial: Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
Study Status: Completed
Recruit Status: RECRUITING
Condition: Bronchiolitis
Study Type: OBSERVATIONAL
Official Title: EPINIR-BRONCHIO : Evaluation Pragmatique de l'Impact du NIrsevimab Sur le Recours Aux uRgences Pour BRONCHIOlite Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOli
Brief Summary:
In July 2023, the Food and Drug Administration approved nirsevimab (Beyfortus®), a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection (Bronchiolitis) among infants and young children.In Europe, The European Medicines Agency approved the use of BEYFORTUS in October 2022.In France, The Haute Autorité de Santé (HAS) approved the use of BEYFORTUS in July 2023 starting in September 2023.Beyfortus is administered as a single intramuscular injection prior…
Read more